Molecular mechanisms of cisplatin resistance in ovarian cancer DOI Creative Commons

Chenying Jiang,

Chenjun Shen,

Maowei Ni

et al.

Genes & Diseases, Journal Year: 2023, Volume and Issue: 11(6), P. 101063 - 101063

Published: Aug. 2, 2023

Ovarian cancer is one of the most common malignant tumors female reproductive system. The majority patients with advanced ovarian are mainly treated cisplatin-based chemotherapy. As widely used first-line anti-neoplastic drug, cisplatin produces therapeutic effects through multiple mechanisms. However, during clinical treatment, resistance has gradually emerged, representing a challenge for patient outcome improvement. mechanism resistance, while known to be complex and involve many processes, remains unclear. We hope provide new direction pre-clinical studies this review on methods overcome drug resistance.

Language: Английский

Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects DOI

Asal Jalal Abadi,

Sepideh Mirzaei, Mahmood Khaksary Mahabady

et al.

Phytotherapy Research, Journal Year: 2021, Volume and Issue: 36(1), P. 189 - 213

Published: Oct. 25, 2021

Abstract Curcumin is a phytochemical isolated from Curcuma longa with potent tumor‐suppressor activity, which has shown significant efficacy in pre‐clinical and clinical studies. stimulates cell death, triggers cycle arrest, suppresses oncogenic pathways, thereby suppressing cancer progression. Cisplatin (CP) DNA damage apoptosis chemotherapy. However, CP adverse effects on several organs of the body, drug resistance frequently observed. The purpose present review to show function curcumin decreasing CP's impacts improving its antitumor activity. administration reduces ROS levels prevent normal cells. Furthermore, can inhibit inflammation via down‐regulation NF‐κB maintain organs. nanoformulations reduce hepatoxicity, neurotoxicity, renal toxicity, ototoxicity, cardiotoxicity caused by CP. Notably, potentiates cytotoxicity mediating death arrest. Besides, STAT3 NF‐ĸB as tumor‐promoting enhance sensitivity resistance. targeted delivery tumor cells be mediated nanostructures. In addition, derivatives are also able CP‐mediated side effects, increase against various types.

Language: Английский

Citations

154
Mechanistic Action of Cell Cycle Arrest and Intrinsic Apoptosis via Inhibiting Akt/mTOR and Activation of p38-MAPK Signaling Pathways in Hep3B Liver Cancer Cells by Prunetrin—A Flavonoid with Therapeutic Potential DOI Open Access
Abuyaseer Abusaliya,

Se Hyo Jeong,

Pritam Bhagwan Bhosale

et al.

Nutrients, Journal Year: 2023, Volume and Issue: 15(15), P. 3407 - 3407

Published: July 31, 2023

Hepatocellular carcinoma (HCC) has a poor prognosis and low survival rate. Drugs without side effects are desperately needed since chemotherapy negative effect on the host cells. Previous research firmly established that plant-based compounds have significant bioactivities impact host. Flavonoids, in particular, class of with both anti-inflammatory anti-cancer properties. Prunetrin (PUR) is glycosyloxyisoflavone (Prunetin 4'-O-glucoside) derived from Prunus sp., its other form, called prunetin, showed optimistic results an anti-cancerous study. Hence, we aimed to discover ability prunetrin liver cancer Hep3B Our cytotoxicity PUR can decrease cell viability. The colony formation assay confirms this strongly correlates results. Prunetrin, dose-dependent manner, arrested cycle G2/M phase decreased expression cyclin proteins such as Cyclin B1, CDK1/CDC2, CDC25c. treatment also promoted strong cleavage two important apoptotic hallmark PARP caspase-3. It apoptosis occurs through mitochondrial pathway increased cleaved caspase-9 levels pro-apoptotic protein Bak. Bak was significantly declining anti-apoptotic Bcl-xL. Next, it inhibits mTOR/AKT signaling pathways, proving includes decreases viability by suppressing these pathways. Further, observed activation p38-MAPK dose-dependent. Taken together, they provide evidence cells arresting via p38 inhibiting mTOR/AKT.

Language: Английский

Citations

19
Tumor-derived exosomal non-coding RNAs as diagnostic biomarkers in cancer DOI

Nasim Ebrahimi,

Ferdos Faghihkhorasani,

Siavash Seifollahy Fakhr

et al.

Cellular and Molecular Life Sciences, Journal Year: 2022, Volume and Issue: 79(11)

Published: Oct. 29, 2022

Language: Английский

Citations

26
Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression DOI

Lihua Fu,

Dan Zhang,

Nuo Yi

et al.

Human Cell, Journal Year: 2022, Volume and Issue: 35(5), P. 1560 - 1576

Published: July 30, 2022

Language: Английский

Citations

23
Exosome-derived proteins in gastric cancer progression, drug resistance, and immune response DOI Creative Commons
Jiayu Wang, Huan Zhang, Juntao Li

et al.

Cellular & Molecular Biology Letters, Journal Year: 2024, Volume and Issue: 29(1)

Published: Dec. 24, 2024

Abstract Gastric cancer (GC) represents a prevalent malignancy globally, often diagnosed at advanced stages owing to subtle early symptoms, resulting in poor prognosis. Exosomes are extracellular nano-sized vesicles and secreted by various cells. Mounting evidence indicates that exosomes contain wide range of molecules, such as DNA, RNA, lipids, proteins, play crucial roles multiple cancers including GC. Recently, with the rapid development mass spectrometry-based detection technology, researchers have paid increasing attention exosomal cargo proteins. In this review, we discussed origin diagnostic prognostic proteins Moreover, summarized biological functions GC processes, proliferation, metastasis, drug resistance, stemness, immune response, angiogenesis, traditional Chinese medicine therapy. summary, review synthesizes current advancements associated GC, offering insights could pave way for novel therapeutic strategies foreseeable future.

Language: Английский

Citations

6
Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells DOI Open Access
Peter Wai Tik Lee,

Lina Rochelle Koseki,

Takao Haitani

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(9), P. 1729 - 1729

Published: April 29, 2024

In hypoxic regions of malignant solid tumors, cancer cells acquire resistance to conventional therapies, such as chemotherapy and radiotherapy, causing poor prognosis in patients with cancer. It is widely recognized that some the key genes behind this are hypoxia-inducible transcription factors, e.g., factor 1 (HIF-1). Since HIF-1 activity suppressed by two representative 2-oxoglutarate-dependent dioxygenases (2-OGDDs), PHDs (prolyl-4-hydroxylases), FIH-1 (factor inhibiting 1), inactivation 2-OGDD has been associated therapy activation HIF-1. Recent studies have also revealed importance hypoxia-responsive mechanisms independent its isoforms (collectively, HIFs). article, we collate accumulated knowledge HIF-1-dependent responsible for anticancer drugs briefly discuss interplay between hypoxia responses, like EMT UPR, chemoresistance. addition, introduce a novel HIF-independent mechanism, which epigenetically mediated an acetylated histone reader protein, ATAD2, recently clarified.

Language: Английский

Citations

5
Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines DOI Open Access

Kieran Caberto Huni,

Jacky Cheung,

Madeline Sullivan

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(2), P. 1244 - 1244

Published: Jan. 8, 2023

Recent advances have suggested that non-coding miRNAs (such as miR-21, miR-27, miR-145, miR-155, miR-365, miR-375 and miR-494) may be involved in multiple aspects of oral cancer chemotherapeutic responsiveness. This study evaluated whether these specific are correlated with responsiveness to chemotherapies, including Paclitaxel, Cisplatin Fluorouracil (5FU). Commercially available well-characterized squamous cell carcinoma lines (SCC4, SCC9, SCC15, SCC25 CAL27) revealed differing resistance chemosensitivity agents-with SCC9 demonstrating the most all agents. were also only expressed miR-375, did not express miR-27. In addition, expression was associated upregulation Rearranged L-myc fusion (RLF) downregulation Centriolar protein B (POC1), whereas lack miR-27 Nucleophosmin 1 (NPM1) expression. These data important regulatory pathways mechanisms proliferation must explored future studies potential therapeutic interventions.

Language: Английский

Citations

12
Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition DOI Creative Commons

Qingyi Hu,

Tao Huang

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(10), P. 8939 - 8939

Published: May 18, 2023

Cyclin-dependent kinases (CDKs) regulate cell division at multiple levels. Aberrant proliferation induced by abnormal cycle is a hallmark of cancer. Over the past few decades, several drugs that inhibit CDK activity have been created to stop development cancer cells. The third generation selective CDK4/6 inhibition has proceeded into clinical trials for range cancers and quickly becoming backbone contemporary therapy. Non-coding RNAs, or ncRNAs, do not encode proteins. Many studies demonstrated involvement ncRNAs in regulation their expression By interacting with important regulators, preclinical may decrease increase treatment outcome inhibition. As result, cycle-associated act as predictors efficacy perhaps present novel candidates tumor therapy diagnosis.

Language: Английский

Citations

12
Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway DOI
Huasong Lu, Jinliang Kong, Shuangqi Cai

et al.

Molecular Biology Reports, Journal Year: 2024, Volume and Issue: 51(1)

Published: June 1, 2024

Language: Английский

Citations

4
MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route DOI Open Access
Butong Sun,

Nanjun Hu,

Dan Cong

et al.

Bioengineered, Journal Year: 2021, Volume and Issue: 12(1), P. 3219 - 3228

Published: Jan. 1, 2021

MicroRNAs exert crucial effects in the drug resistance. The purpose of this research was to investigate miR-25-3p on DDP resistance NSCLC. We used RT-qPCR evaluate expression miR-25-3p. Cell growth determined using MTS assay. Cellular bio-activity analyzed via Colony formation, Annexin V/PI, and Transwell Luciferase reporter assay determine PTEN binding. Western blot PTEN, PI3K, p-AKT/AKT expression. In-vivo study tumor growth. Expression is increased NSCLC cisplatin resistant A549 H1299 cells. Furthermore, mimic enhanced resistance, accelerated cell invasion metastasis. Moreover, resulted activation PTEN/PI3K/AKT pathway. However, inhibitors exhibited opposite trend. further identified as a potential target knockout promoted while displayed effects. Interestingly, boosted cells vivo, reduced in-vivo volume. MiR-25-3p/PTEN/PI3K/AKT axis might accelerate tolerance NSCLC, which may serve for chemotherapy

Language: Английский

Citations

24